Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Myeloid 1Lymphoid 1Head & Neck 1Genitourinary 1CNS 1Breast 1

Conditions

Lung Neoplasms 12Ovarian Neoplasms 8Carcinoma, Non-Small-Cell Lung 7Fallopian Tube Neoplasms 6Urinary Bladder Neoplasms 5Colorectal Neoplasms 5Carcinoma, Hepatocellular 5Squamous Cell Carcinoma of Head and Neck 4Pancreatic Neoplasms 4Carcinoma, Renal Cell 4Neoplasm Metastasis 3Mouth Neoplasms 3Melanoma 3Leukemia, Lymphocytic, Chronic, B-Cell 3Glioblastoma 3Endometrial Neoplasms 3Cholangiocarcinoma 3Thyroid Neoplasms 2Small Cell Lung Carcinoma 2Prostatic Neoplasms 2Oropharyngeal Neoplasms 2Nasopharyngeal Carcinoma 2Mycosis Fungoides 2Multiple Myeloma 2Lymphoma, T-Cell 2Lymphoma, Large-Cell, Anaplastic 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, B-Cell 2Lymphoid Interstitial Pneumonia 2Laryngeal Neoplasms 2

Interventions

temsirolimus 1Valproic Acid 1Specimen Handling 1Sirolimus 1Immunoglobulin G 1Disulfides 1Cetuximab 1Biopsy 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Soft Tissue Neoplasms × Disulfides × 90 days × Clear all
NCT01552434 2026-05-15

Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

M.D. Anderson Cancer Center

Phase 1 Terminated
154 enrolled
BreastCNSGenitourinaryHead & NeckLymphoidMyeloidSarcoma

Breast Neoplasms, Carcinoma, Transitional Cell, Endocrine Gland Neoplasms, Castleman Disease, Mouth Neoplasms, Neoplasm Metastasis, Neoplasms, Pharyngeal Neoplasms, Recurrence, Sarcoma, Soft Tissue Neoplasms, Thyroid Neoplasms, Urologic Neoplasms, Neurofibromatosis 2, Lymphangioleiomyomatosis, Neoplasms, Mesothelial, Erdheim-Chester Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡